Table 3 Comprehensive clinical data, medications employed and risk factors for relapse in both cohorts
Parameters | Relapsed patients (n = 83, eyes = 126) | Non-relapsed patients (n = 205, eyes = 356) | Univariate | Multivariate | ||
|---|---|---|---|---|---|---|
OR (95% CI) | P Value | OR (95% CI) | P Value | |||
Age (years) (M-IQR) | 31 (15–48) | 31 (14–44) | 1.006 (0.992–1.020) | 0.398 | NA | NA |
Gender (male/female) (n, %) | 32 (38.6)/51(61.4) | 98 (47.8)/107(52.2) | 1.460 (0.868–2.455) | 0.154 | NA | NA |
Course of disease (years) (M-IQR) | 3.25 (1.58–5.33) | 2.17 (1.08-4.00) | 1.054 (0.995–1.116) | 0.075 | 1.082 (1.016–1.151) | 0.013 |
BCVAa (logMAR, M-IQR) | 0.00 (0.00-0.22) | 0.00 (0.00-0.15) | 0.831 (0.518–1.333) | 0.443 | NA | NA |
The anterior chamber cell grade recorded as 0b (eyes, %) | 103 (81.7) | 295 (82.9) | 0.926 (0.545–1.572) | 0.776 | NA | NA |
Infectious uveitis (n, %) | 1 (1.2) | 8 (2.2) | 3.330 (0.410-27.051) | 0.260 | NA | NA |
Anatomical classification (n, %) | ||||||
Anterior uveitis | 10 (12.0) | 20 (9.8) | 1 | 0.565 | NA | NA |
Intermediate, posterior or panuveitis | 73 (88.0) | 185 (90.2) | 0.789 (0.352–1.767) | NA | NA | NA |
Uveitis-related systemic diseases (n, %) | ||||||
Vogt-Koyanagi-Harada disease | 14 (16.9) | 33 (16.1) | 0.946 (0.477–1.875) | 0.873 | NA | NA |
Behcet’s disease | 4 (4.8) | 22 (10.7) | 2.374 (0.792–7.115) | 0.123 | NA | NA |
Ankylosing Spondylitis | 9 (10.8) | 10 (4.9) | 0.422 (0.165–1.079) | 0.072 | 0.406 (0.145–1.133) | 0.085 |
Other diseasesc | 6 (7.2) | 10 (4.9) | 0.658 (0.231–1.873) | 0.433 | NA | NA |
Other systemic diseases (n, %) | ||||||
Hypertension | 9 (10.8) | 12 (5.9) | 0.511 (0.207–1.264) | 0.146 | NA | NA |
Diabetes | 2 (2.4) | 9 (4.4) | 1.860 (0.393–8.796) | 0.434 | NA | NA |
Malignancy | 1 (1.2) | 3 (1.5) | 1.218 (0.125–11.879) | 0.865 | NA | NA |
Time since the last relapse > 1 year (n, %) | 20 (24.1) | 82 (40.0) | 0.476 (0.268–0.847) | 0.012 | 0.335 (0.177–0.632) | 0.001 |
Systemic medicationd(n, %) | ||||||
Prednisone | 36 (43.4) | 91 (44.4) | 0.960 (0.574–1.605) | 0.875 | NA | NA |
Immunosuppressants | 31 (37.3) | 103 (50.2) | 0.590 (0.350–0.995) | 0.048 | NA | NA |
Cyclosporin A | 4 (4.8) | 3 (1.5) | 3.409 (0.746–15.578) | 0.114 | NA | NA |
Methotrexate | 22 (26.5) | 82 (40.0) | 0.541 (0.308–0.949) | 0.032 | 0.516 (0.288–0.926) | 0.026 |
Mycophenolate mofetil | 8 (9.6) | 19 (9.3) | 1.044 (0.438–2.489) | 0.922 | NA | NA |
Azathioprine | 0 | 1 (0.5) | 0 | 1.000 | NA | NA |
Adalimumab | 22 (26.5) | 72 (35.1) | 0.666 (0.378–1.173) | 0.159 | NA | NA |
Types of systemic medications (n, %) | 205 | |||||
0 | 32 (38.6) | 58 (28.3) | 1 | 0.349 | NA | NA |
1 | 20 (24.1) | 55 (26.8) | 0.659 (0.337–1.287) | NA | NA | NA |
2 | 19 (22.9) | 66 (32.2) | 0.558 (0.288–1.081) | NA | NA | NA |
3 types and above | 12 (14.5) | 26 (12.7) | 0.738 (0.324–1.682) | NA | NA | NA |
Self-delayed Medicationse (n, %) | 19 (22.9) | 39 (19.0) | 1.264 (0.680–2.348) | 0.459 | NA | NA |
Vaccination (n, %) | 76 (91.6) | 192 (93.7) | 1.360 (0.523–3.540) | 0.528 | NA | NA |